On February 20, 2018, the U.S. Supreme Court issued a brief order declining to review a federal appeals court decision that requires exacting antitrust scrutiny for virtually any agreement between a brand-name drug company and a generic drug company to settle a patent-infringement dispute. The decision was a setback for WLF, which filed a brief urging the Court to review the case. WLF argued that the appeals court decision expands antitrust liability dramatically and makes it almost impossible for litigants to settle drug-patent disputes. WLF asserted that antitrust litigation is inefficient and extremely expensive, and thus that courts ought to be encouraging settlements.